Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trial of Accelerated Adjuvant Chemotherapy With Capecitabine in Early Breast Cancer.

Next Previous
Trial Profile

Trial of Accelerated Adjuvant Chemotherapy With Capecitabine in Early Breast Cancer.

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capecitabine (Primary) ; Epirubicin (Primary) ; Cyclophosphamide; Cyclophosphamide; Fluorouracil; Methotrexate; Pegfilgrastim
  • Indications Early breast cancer; Male breast cancer
  • Focus Therapeutic Use
  • Acronyms TACT2

    • Most Recent Events

    • 02 Nov 2023 Results (n=1493) of QOL substudy assessing the effect of chemotherapies on psychological distress, physical symptoms, and functional domains published in the Lancet Oncology
    • 19 Mar 2014 Efficacy results on capecitabine vs CMF presented at the 9th European Breast Cancer Conference.
    • 19 Mar 2014 Accruel to date is 97% according to UK Clinical Research Network
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top